DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Special Investigation Of Genotropin Long Follow-Up For Patients With A Small For Gestational Age (SGA)

Information source: Pfizer
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Small for Gestational Age (SGA)

Intervention: Somatropin (Drug)

Phase: N/A

Status: Active, not recruiting

Sponsored by: Pfizer

Official(s) and/or principal investigator(s):
Pfizer CT.gov Call Center, Study Director, Affiliation: Pfizer


The objective of this surveillance is to collect Safety and Effectiveness information for Long term Use of Somatropin for Patients with a Small for Gestational Age (SGA).

Clinical Details

Official title: Special Investigation For Genotropin(Sga Long Follow-up)

Study design: Observational Model: Cohort, Time Perspective: Retrospective

Primary outcome:

Change in growth rate SD score for calendar age

Change in height SD score for calendar age

Secondary outcome: Final height

Detailed description: All the patients whom an investigator prescribes Genotropin should be registered consecutively until the number of subjects reaches target number in order to extract patients enrolled into the investigation at random.


Minimum age: N/A. Maximum age: 20 Years. Gender(s): Both.


Inclusion Criteria:

- A patient who was administered Somatropin (Genotropin).

Exclusion Criteria:

- N/A.

Locations and Contacts

Additional Information

To obtain contact information for a study center near you, click here.

Starting date: September 2013
Last updated: July 30, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017